Other important factors, including isocitrate dehydrogenase (IDH) enzymes, that were previously found as mutated in gliomas,34 and biomarkers (e.g., methylation of the O6‐methylguanine‐DNA methyltransferase (MGMT) promoter), were found to be associated with the silencing of MGMT as a favorable outcome.8 The gene discussed is IDH3A; the disease is central nervous system cancer.